Prescribing Practice & Policy
GLP-1 Agonists in Uncharted Territory: What Prescribers Must Know About Expanded Indications, Coverage Gaps, and Ethical Practice in 2024
GLP-1 receptor agonists have moved far beyond their origins as glucose-lowering agents, generating intense clinical interest and patient demand across weight management, cardiovascular medicine, and emerging therapeutic areas. Yet the prescribing landscape in 2024 is defined as much by insurance inconsistencies and ethical complexity as it is by promising clinical evidence. This article provides healthcare providers with practical guidance on navigating FDA approvals, off-label prescribing oblig